BRCA

New data on vaginal ring support benefits for HIV preventionInterim data from two studies of a dapivirine vaginal ring—DREAM and HOPE—lend further credence to the potential benefits of using the device for HIV prevention. Plus: FDA authorizes direct-to-consumer BRCA1/BRCA2 test. Also: A new Zika virus test extends window for accurate diagnosis.
First direct-to-consumer test for breast cancer risk hits market
First direct-to-consumer test for breast cancer risk hits marketFDA approved the first direct-to-consumer test for three specific BRCA1/BRCA2 breast cancer gene mutations.
Top 3 new cancer drugs
Top 3 new cancer drugsThe first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.
Seven diseases benefiting from genetic tests
Seven diseases benefiting from genetic testsGenetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
Hereditary cancers in gynecology:  What clinicians need to know
Hereditary cancers in gynecology: What clinicians need to knowThe contribution of hereditary cancer syndromes to many gynecologic malignancies has been increasingly recognized over the past decade. As they often serve as primary care providers, ob/gyns are uniquely positioned to help identify at-risk women before they develop cancer.
Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Failure to recommend genetic testing in breast cancerIs this the next wave of medical professional liability lawsuits?
Who is being tested for BRCA?A study looks at who is being tested for BRCA mutations as testing becomes more common. Also, a look at the impact of Zika virus on birth defects using benchmark data. Plus: How is the United States doing with infant mortality?
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Beyond BRCA: Promising results with multigene testing for breast cancerResults of a multi center observational study suggest that testing for a panel of genes may be the wave of the future for hereditary breast and ovarian cancer and alter the course of clinical management.